Next Article in Journal
Visualization and Interpretation of Multivariate Associations with Disease Risk Markers and Disease Risk—The Triplot
Next Article in Special Issue
Chemical Aspects of Gut Metabolism of Flavonoids
Previous Article in Journal
Effects of Water Availability in the Soil on Tropane Alkaloid Production in Cultivated Datura stramonium
Previous Article in Special Issue
Role of Intestinal Microbiota in Metabolism of Gastrodin In Vitro and In Vivo
Open AccessArticle

Effects of Gut Microbiota on the Bioavailability of Bioactive Compounds from Ginkgo Leaf Extracts

by 1,†, 2,†, 2,* and 1,*
Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do 15588, Korea
Neurobiota Research Center, Department of Life and Nanopharmaceutical Sciences and College of Pharmacy, Kyung Hee University, Seoul 02447, Koera
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Metabolites 2019, 9(7), 132;
Received: 5 June 2019 / Revised: 1 July 2019 / Accepted: 3 July 2019 / Published: 5 July 2019
(This article belongs to the Special Issue Gut Metabolism of Natural Products)
Ginkgo leaf extract (GLE) is a popular herbal medicine and dietary supplement for the treatment of various diseases, including cardiovascular disease. GLE contains a variety of secondary plant metabolites, such as flavonoids and terpenoids, as active components. Some of these phytochemicals have been known to be metabolized by gut microbial enzymes. The aim of this study was to investigate the effects of the gut microbiota on the pharmacokinetics of the main constituents of GLE using antibacterial-treated mice. The bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, isorhamnetin, kaempferol, and quercetin pharmacokinetic profiles of orally administered GLE (600 mg/kg), with or without ciprofloxacin pretreatment (150 mg/kg/day for 3 days), were determined. In the antibacterial-treated mice, the maximum plasma concentration (Cmax) and area under the curve (AUC) of isorhamnetin were significantly (p < 0.05) increased when compared with the control group. The Cmax and AUC of kaempferol and quercetin (other flavonol glycosides) were slightly higher than those of the control group, but the difference was not statistically significant, while both parameters for terpenoids of GLE showed no significant difference between the antibacterial-treated and control groups. These results showed that antibacterial consumption may increase the bioavailability of isorhamnetin by suppressing gut microbial metabolic activities. View Full-Text
Keywords: gut microbiota; ginkgo leaf extracts; flavonoid; metabolism; pharmacokinetics gut microbiota; ginkgo leaf extracts; flavonoid; metabolism; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Choi, M.S.; Kim, J.-K.; Kim, D.-H.; Yoo, H.H. Effects of Gut Microbiota on the Bioavailability of Bioactive Compounds from Ginkgo Leaf Extracts. Metabolites 2019, 9, 132.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop